Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China ...Middle East

DURHAM, N.C. and BEIJING, March 29, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced...

Read More Details
Finally We wish PressBee provided you with enough information of ( Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China )

Also on site :

• Anne Burrell's Husband Looks Somber in First Photo Since Food Network Star's Death
• Iran threatens US bases in Middle East, asserts nuclear facilities undamaged
• Las negociaciones “no tienen sentido” a menos que Israel detenga los ataques, dice un portavoz del Gobierno iraní a CNN